The News Review:
- Canadian Blood Services scientist invents potential alternative for…
- International team analyzes human genetic variation in key immune…
- Breaker Energy Ltd. announces significant light oil discovery and…
- Elan and Transition Therapeutics Inc. Announce Global Collaboration…
- 1010 WINS - On-Air, Online, On Demand - *
- DRAXIS Files DRAXIMAGE(R) Sestamibi in Europe
Canadian Blood Services scientist invents potential alternative for…
Canada NewsWire - Canada NewsWire (press release) - Mar 24, 2008
Lazarus
in the laboratory. Lazarus’ article in Nature Medicine can be viewed online at.
International team analyzes human genetic variation in key immune…
Canada NewsWire - Canada NewsWire (press release) - Mar 25, 2008
“This new map will be a key resource for researchers to use to find genes
affecting health, disease, and responses to medications,” said senior author
Dr. Rioux, PhD, who is associate professor of medicine at the UdeM and
at the MHI where he works as a researcher and director of the Laboratory in
Genetics and Genomic Medicine of Inflammation (. org), Visiting
Scientist of the Broad Institute of MIT and Harvard, and holder of the Canada
Research Chair in Genetics and Genomic Medicine of Inflammation… (2006) A high resolution HLA and SNP haplotype
map for disease association studies in the extended human MHC. Nature
Genetics doi:10. de Bakker1,2,16, Gil McVean3,16, Pardis C. Sabeti1,16, Marcos
M. Miretti4,16, Todd Green(1), Jonathan Marchini(3), Xiayi Ke5, Alienke
J.
Breaker Energy Ltd. announces significant light oil discovery and…
Canada NewsWire - Canada NewsWire (press release) - Mar 25, 2008
The structure is contained within four quarter sections held 100% by
Breaker. Up to 3 offsetting locations are possible, however the 13-15 location
should be able to drain the bulk of the Granite Wash oil given its high
structural position and excellent reservoir quality. Follow up locations will
target Granite Wash attic oil, Beaverhill Lake step-outs, and Slave Point
seismic anomalies; underlining the multi-zone nature of the new field
discovery. Breaker’s current internal estimate of recoverable light oil for the
13-15 discovery ranges from 400,000 to over 1 million barrels. Breaker’s early 2006 discoveries at Girouxville have continued their
development… Preparations are underway for another similar round of drilling in late summer
or early fall, with continued flexibility in targeting oil or natural gas
depending on pricing. Investigation into the implementation of a waterflood in
the Sparky play has proved promising, and pilot schemes are under evaluation. Medicine Hat
In the second quarter Breaker drilled 3 exploratory gas wells at a 100%
success rate. Two will be equipped and tied-in in the third quarter. Breaker
was successful at the July 12th landsale acquiring new 100% lands in its
Medicine Hat area, providing access to future exploration locations. Irricana and Millard Lake
Breaker has taken over operatorship of both properties subsequent to
recent closing of the acquisitions.
Elan and Transition Therapeutics Inc. Announce Global Collaboration…
Canada NewsWire - Canada NewsWire (press release) - Mar 24, 2008
com or by dialling
1 (888) 633-8341 or (416) 620-5690. About the AZD-103 Drug
AZD-103 is a novel therapeutic agent in Phase 1 clinical development for
the treatment of Alzheimer’s disease that has the potential to both reduce
disease progression and improve symptoms such as cognitive function. As
reported recently in a Nature Medicine publication, oral treatment with
AZD-103 reduced accumulation of amyloid beta and amyloid beta plaques in the
brain, and reduced or eliminated learning deficits in a leading transgenic
mouse model of Alzheimer’s disease. In addition, AZD-103 is well positioned as
a potential Alzheimer’s therapy as it is a small molecule, crosses the blood
brain barrier and has exhibited a favorable safety profile. About Alzheimer’s disease
Alzheimer’s disease is a progressive brain disorder that gradually
destroys a person’s memory and ability to learn, reason, make judgments,
communicate and carry out daily activities. The disease affects more than
4 million Americans and approximately 20 million people worldwide, and with an
aging population incidence of Alzheimer’s disease is expected to double over
the next 20 years. Currently approved Alzheimer’s therapies treat some disease
symptoms but do not reverse or slow down disease progression.
1010 WINS - On-Air, Online, On Demand - *
1010wins.com - Mar 25, 2008
So they then tested the drug in mice with Duchenne muscular dystrophy. After six months of treatment, the mice showed a significant reduction in muscle damage. The mice showed increased grip strength in their fore- and hind-limbs and experienced less fatigue in repetitive tests, the researchers reported in Monday’s online issue of the journal. Losartan was approved for use as a blood pressure medication in 1995 by the.
DRAXIS Files DRAXIMAGE(R) Sestamibi in Europe
Canada NewsWire - Canada NewsWire (press release) - Mar 24, 2008
(TSX: DAX) (NASDAQ: DRAX), has taken another significant
step in its product development strategy with the filing of its DRAXIMAGE(R)
Sestamibi with European regulatory authorities. DRAXIMAGE(R) Sestamibi is a
generic kit for the preparation of Tc-99m Sestamibi for injection, which is an
imaging agent used in myocardial perfusion imaging (MPI) to evaluate blood
flow to the heart and is the largest radiopharmaceutical product in the
nuclear medicine market segment. “Filing DRAXIMAGE(R) Sestamibi in Europe marks another milestone in our
comprehensive plan to pursue major MPI markets globally,” said Jean-Pierre
Robert, President of DRAXIS Specialty Pharmaceuticals Inc. , the operating
subsidiary of DRAXIS Health. “DRAXIMAGE(R) Sestamibi is one of our highest
priority growth drivers and the filing of marketing applications in Europe and
in the U… You
should not place undue reliance on any forward-looking statement, which speaks
only as of the date made. These statements are not guarantees of future performance. By their
nature, forward-looking statements involve numerous assumptions, known and
unknown risks, uncertainties and other factors that may cause the actual
results or performance of the Company to be materially different from such
statements or from any future results or performance implied thereby. Factors
that could cause the Company’s results or performance to differ materially
from a conclusion, forecast or projection in the forward-looking statements
include, but are not limited to:. Key Information - Risk Factors” in
the Annual Report Form 20-F filed by the Company with the United
States Securities and Exchange Commission and which is also filed as
the Company’s Annual Information Form with Canadian securities
regulators. >>
For additional information with respect to certain of these and other
factors, and relating to the Company generally, reference is made to the
Company’s most recent filings with the United States Securities and Exchange
Commission (available on EDGAR at www.
Leave a Comment